Company Overview and News

1
EMR Capital Explores Sale of Copper Mine in Australia - Bloomberg

2017-11-03 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
Hindalco Q4 profit rises 25% to Rs503 crore

2017-05-30 livemint
Hindalco’s total income on a standalone basis increased to Rs 11,969.6 crore, over Rs 9,472 crore in the year-ago period

 
Hindalco Q1 profit jumps fivefold to Rs294 crore as costs decline

2016-08-12 livemint
Hindalco net sales, however, fell about 12% to Rs7,501.39 crore from Rs8,517.29 crore a year earlier due to a sharp decline in realizations

 
Metals X Ltd raises $100.6M, to demerge gold division

2016-08-04 proactiveinvestors.com.au
Metals X Ltd (ASX:MLX) has completed an institutional placement to raise $100.6 million and is now undertaking a share purchase plan of to raise up to $15 million. The company is also looking to demerge its gold division from the remainder of its diversified base metal assets, following the takeover of Aditya Birla Minerals Ltd’s (ASX:ABY) Nifty copper mine. Over the past few years, Metals X has made a number of shrewd acquisitions and has built a formidable diversified mining company.

 
Hindalco's Q1 net plunges 95% to Rs 44.81 crore

2016-07-22 moneycontrol
The flagship firm of the Aditya Birla Group had clocked a net profit of Rs 854.21 crore in the year-ago period, it said in a regulatory filing.

 
Hindalco consolidated Q1 net dips 95% to Rs 44.80 cr

2016-07-21 thehindubusinessline
Aluminium maker Hindalco today reported a steep 95 per cent decline in its consolidated net profit at Rs 44.81 crore for the June quarter, mainly hit by impairment charges and write downs.

 
Hindalco’s Q1 Net plunges 95% to Rs 44.81 crore

2016-07-21 financialexpress
Aluminium maker Hindalco today reported a steep 95 per cent decline in its consolidated net profit at Rs 44.81 crore for the June quarter, mainly hit by impairment charges and write downs. The flagship firm of the Aditya Birla Group had clocked a net profit of Rs 854.21 crore in the year-ago period, it said in a regulatory filing. Total consolidated income of the firm also declined, albeit by 4 per cent, to Rs 1,00,042.

 
Hindalco’s Q1 net profit plunges 95% to Rs44.81 crore

2016-07-21 livemint
Hindalco’s total consolidated income also declined, albeit by 4%, to Rs1,00,042.16 crore in Q1 against Rs1,04,281.10 crore during the same period of 2015-16

 
Wipro may drop on weak Q1 results

2016-07-20 indiainfoline
Wipro's consolidated net profit attributable to equity holders fell 6.38% to Rs 2051.80 crore on 11.12% growth in gross revenue to Rs 13599.20 crore in Q1 June 2016 over Q1 June 2015. The results are as per International Financial Reporting Standards (IFRS). Revenue from IT services business rose 2.6% to $1,930.8 million in Q1 June 2016 over Q4 March 2016. Non-GAAP constant currency IT services segment revenue in dollar terms grew 2% sequentially and 9.

 
RBI approves takeover of Hindalco’s Australian arm by Metal X

2016-07-19 financialexpress
Aluminium maker Hindalco today said Reserve Bank of India (RBI) has approved Australian miner Metal X’s improved takeover offer for its subsidiary Aditya Birla Minerals Ltd (ABML).

 
 
MLX: ABY Takeover Update

2016-05-03 asx.com.au

 
Response to ASX Aware Query

2016-05-02 asx.com.au

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

20h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

20h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...